Overall verdict
Neutral
6.1/10
1-year performance
-13.62%
Score breakdown
Down 13.6% over 1 year, 39% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 3.2/10.
30 analysts, target +0.1% vs the price.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism ;
traditional brain and open skull based surgical procedures products ; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications.
The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Kevin Lobo
Founded
1941
Employees
56 000
Revenue / employee
448 500 USD
Next earnings
January 28, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.10%
- Bank of New York Mellon Corp0.92%
- FMR LLC0.24%
- Rest of the register96.74%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
389.33 USD
52-week low
267.00 USD
1-year performance
-13.62%
Declining
Year-to-date performance
-10.46%
Declining
Drawdown
-19.22%
Marked drawdown
Position in the 52-week range
39% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| Stryker | $146,950 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.6 times as much as the world ETF.
- Worst fall:-54 % between December 2007 and February 2009. $10,000 placed at the top fell to $4,552. The world ETF, at worst: -53 %. Back to its high in 53 months.
Stryker earned 2 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Stryker: $146,950
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 231.80 USD - 255.54 USD (comparables only)
The price implies growth of 8.52% per year; the company grows at 14.84%.
Gross margin 63.2%, net margin 13.8%, ROIC 9.7%, ROE 16.0%.
Net margin
13.78%
Exceptional
Sector 9.11%|S&P 13.40%
Gross margin
63.21%
Fair
Return on equity (ROE)
16.02%
Exceptional
Sector 7.42%|S&P 17.06%
Return on invested capital (ROIC)
9.66%
Exceptional
Free cash flow margin (FCF)
17.39%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.26x
High
Margin stability
4.5 pts
Steady
Revenue to net income
Growth
3.2/10Revenue up 7.6% over 1 year, 11.8% a year over 5, EPS 14.8% a year over 5.
Revenue (trailing 12 months)
26.3Md USD
Revenue growth (1y)
7.64%
Solid
Revenue growth (3y)
36.14%
Solid
EPS growth (1y)
-11.88%
Declining
EPS CAGR (5y)
14.84%
Exceptional
EPS revisions (3 months)
-1.20%
Revised down
Valuation
5.4/10P/E 33.5x, forward P/E 27.1x, EV/EBITDA 18.6x, PEG 2.26. The multiple sits in the 13th percentile of its own 5-year history.
P/E (TTM)
33.5x
Fair
Sector 29.2x|S&P 23.6x
Forward P/E
27.1x
Fair
EV / EBITDA
18.6x
Expensive
Sector 14.2x|S&P 15.5x
PEG
2.26
Very expensive
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
243.67 USD
Overvalued
P/E vs its own 5-year history
among the 13% lowest valuations
Far cheaper than usual
Market cap
120Md USD
Financial strength
7.0/10Cash covers 21.2% of the debt, net debt/EBITDA 1.7x.
Net debt / EBITDA
1.7x
Tight
Gearing (net debt / equity)
51.85%
Solid
Cash
3.3Md USD
Cash / market cap
2.73%
Stretched
Cash / total debt
21.19%
Tight
Interest coverage
10.0x
Solid
Net debt
12.2Md USD
Equity
23.5Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 324.29 USD
- MM20308.34
- MM50292.18
- MM200322.56
- RSI 1460.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.65%
200-day average slope, 3 months
-5.62%
50-day average slope, 1 month
-3.87%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
3.19 % per day
Volatility change
+41.71%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 11.60 (10) | 14.83 (29) | 26 813 (27) | 7 819 (16) | 4 440 (9) |
| 2027 | 13.84 (11) | 16.29 (29) | 28 722 (28) | 8 325 (17) | 5 278 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 187 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IDXX | 6.3 | 5.7 | 55.4Md USD | 47.4x | 25.4 % | 9.9 % | 54.9 % | 0.5x | 2.3 % | -1.2 % | ||
| 2 | ISRG | 6.2 | 5.5 | 156Md USD | 54.4x | 25.5 % | 21.7 % | 18.0 % | -1.6x | 2.3 % | -21.8 % | ||
| 3 | MDT | 6.2 | 6.7 | 130Md USD | 25.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 4.7 % | 9.3 % | ||
| 4 | SYK | 6.1 | 6.1 | 120Md USD | 33.5x | 13.8 % | 7.6 % | 9.7 % | 1.7x | 3.8 % | -13.6 % | ||
| 5 | ABT | 6.0 | 5.2 | 189Md USD | 40.3x | 9.8 % | 14.5 % | 6.6 % | 0.5x | 3.6 % | -13.7 % | ||
| 6 | EW | 5.9 | 5.1 | 60.8Md USD | 61.6x | 14.9 % | 10.5 % | 8.9 % | -2.0x | 2.3 % | 25.3 % | ||
| 7 | BSX | 5.6 | 6.4 | 65.4Md USD | 19.1x | 16.6 % | 1.4 % | 9.8 % | 1.8x | 5.1 % | -55.5 % | ||
| 8 | BDX | 5.5 | 5.3 | 58.4Md USD | 51.8x | 7.4 % | -10.5 % | 3.6 % | 2.9x | 4.6 % | 49.4 % | ||
| 9 | SHL | 5.3 | 5.3 | 53.1Md USD | 22.0x | 9.4 % | 7.3 % | 7.3 % | 2.8x | 4.3 % | 0.0 % |
